
|Videos|July 22, 2011
Dr. West Explains the Pemetrexed Clinical Trial
Author(s)H. Jack West, MD
Dr. Jack West from Swedish Cancer Institute Explains the Pemetrexed Clinical Trial
Advertisement
H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, describes progression free survival (PFS) for patients with advanced nonsquamous non—small cell lung cancer (NSCLC) in the PARAMOUNT phase III trial examining continuation maintenance therapy in two randomized arms; one receiving pemetrexed in addition to best supportive care and the other placebo and best supportive care.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































